WO1998057700A1 - System for pancreatic stimulation and glucose measurement - Google Patents

System for pancreatic stimulation and glucose measurement Download PDF

Info

Publication number
WO1998057700A1
WO1998057700A1 PCT/US1998/006832 US9806832W WO9857700A1 WO 1998057700 A1 WO1998057700 A1 WO 1998057700A1 US 9806832 W US9806832 W US 9806832W WO 9857700 A1 WO9857700 A1 WO 9857700A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
stimulus
insulin
stimulating
sensing
Prior art date
Application number
PCT/US1998/006832
Other languages
French (fr)
Inventor
Richard P. M. Houben
Alexis C. M. Renirie
Koen J. Weijand
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to EP98913410A priority Critical patent/EP0989883A1/en
Publication of WO1998057700A1 publication Critical patent/WO1998057700A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/42Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222Evaluating particular parts, e.g. particular organs
    • A61B5/425Evaluating particular parts, e.g. particular organs pancreas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • A61B5/7207Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal of noise induced by motion artifacts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control

Definitions

  • This invention relates to systems for treatment of non-insulin-dependent diabetes mellitus and, in particular, systems for stimulating the pancreas to enhance sensing of beta-cell electrical activity, from which a measure of patient blood glucose level is obtained.
  • NIDDM non-insulin-dependent diabetes mellitus
  • the percentage of NIDDM patients receiving insulin treatment increases with the duration of NIDDM, from an initial rate of about 25 % to about 60% after 20 years.
  • NIDDM a flexible and reliable system and method for measuring glucose level and supplying insulin when and as needed.
  • the human pancreas normally provides insulin for metabolic control. Basically, the insulin acts to promote transport of glucose in body cells.
  • the pancreas has an endocrine portion which, among other functions, continuously monitors absolute blood glucose values and responds by production of insulin as necessary.
  • the insulin-producing cells are beta cells, which are organized with other endocrine cells in islets of Langerhans; roughly 60-80% of the cells in an islet are such beta cells.
  • the islets of Langerhans in turn are distributed in the pancreatic tissue, with islets varying in size from only about 40 cells to about 5,000 cells.
  • beta cells within an islet are coupled by gap junctions, which allow for electrical coupling and communication between neighboring beta cells.
  • the beta cells within the islet undergo periodic depolarization, which is manifested in oscillatory electrical spikes produced by the beta cells, often referred to as a burst which carries on for a number of seconds.
  • the beta cell electrical activity is characterized by a low frequency alternation consisting of a depolarized phase (the burst) followed by a repolarized or hyperpolarized phase which is electrically silent.
  • the relative time spent in the depolarized phase, during which the relatively higher frequency beta cell action potentials are triggered has a sigmoidal relation with blood glucose concentration.
  • the duty cycle, or depolarization portion compared to the quiet portion is indicative of glucose level, and thus of insulin demand. Additionally, the frequency of the spikes during the active period, and likewise the naturally occurring frequency of the bursts (also referred to plateaus) carries information reflective of glucose level.
  • sensing of the beta cell activity from islets of Langerhans in the pancreas may provide information for sensing insulin demand and controlling insulin delivery.
  • Systems which seek to utilize glucose-sensitive living cells, such as beta cells, to monitor blood glucose levels are known in the art.
  • U.S. Patent 5,190,041 discloses capsules containing glucose- sensitive cells such as pancreatic beta cells, and electrodes for detecting electrical activity. The capsules are situated similarly to endogenous insulin-secreting glucose-sensitive cells, and signals therefrom are detected and interpreted to give a reading representative of blood glucose levels.
  • the problem is in reliably sensing the beta cell electrical activity.
  • the system includes a stimulus generator for stimulating the pancreatic beta cells with electric field stimuli so as to provide synchronized burst responses which are relatively free of signal interference and which can be accurately timed.
  • a system and method for improved insulin delivery for an NIDDM patient is based on sensing in-vivo pancreatic beta cell electrical activity, as an indictor for insulin demand.
  • a pancreatic stimulus generator is controlled to deliver synchronized stimulus pulses, i.e., electric field stimuli, to the patient's pancreas at a slow rate, e.g., once every 6-20 seconds.
  • a slow rate e.g., once every 6-20 seconds.
  • the depolarization activity of the cells is sensed and processed to derive an indication of blood glucose level.
  • the system monitors cardiac activity, and controls the delivery of stimulus pulses so that the onset of each beta cell burst is relatively free of interference of the heart's QRS complex.
  • the blood level information obtained from the sensed beta cell activity can be used for automatic control of an insulin pump.
  • the electric field stimuli are delivered to transplanted pancreatic beta cells in order to enhance insulin production, as disclosed in referenced U.S.S.N.08/876, 610.
  • the vagal nerve is stimulated to synchronize.
  • the blood glucose level monitoring may be carried out substantially continuously by an implantable system, or the system may be programmed for periodic measurement and response.
  • measurements may imtiated by application of an external programmer, e.g. , a simple hand-held magnet.
  • blood glucose level may also be monitored by another sensor, such as by examining EKG signals or nerve signals, and the system responds to insulin demand by controlling delivery of insulin from an implantable pump or by stimulating the pancreatic beta cells to enhance insulin production directly by the pancreas, also as disclosed in referenced U.S.S.N. 08/876,610
  • FIG. 1 is a diagram of a human pancreas with electrodes positioned for use in the system of this invention.
  • Fig. 2 A shows two timing diagrams of beta cell electrical activity of islets of Langerhans, the upper diagram having a lower burst duty cycle, while the lower diagram has a higher burst duty cycle;
  • Fig. 2B is a timing diagram showing in greater detail the features of a depolarization burst portion of a cycle as depicted in either diagram of Fig. 2A.
  • Fig. 3 is a block diagram showing the primary functional components of a system in accordance with this invention.
  • Fig. 4 is a flow diagram illustrating the primary steps taken in stimulating pancreatic beta cells and obtaining glucose level information from the insulin- producing beta cells, in accordance with this invention.
  • Fig. 5 A is a simplified flow diagram showing the primary steps of an automatic implantable closed loop insulin-delivery system in accordance with this invention
  • Fig.5B is a simplified flow diagram illustrating the primary steps in a system in accordance with this invention, wherein the system responds to an external programming command. DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • FIG. 1 there is shown a diagram of a human pancreas, with an indication of some of the primary features of the pancreas.
  • An implantable device 20 is illustrated, which suitably contains a stimulus generator and associated electronics, and an insulin pump. Of course, separate devices can be used, as a matter of design choice.
  • a sensing lead 22 is illustrated which connects device 20 to one or more pairs of electrodes illustrated schematically at 25, 26, for use in stimulating and sensing.
  • a lead can be positioned into the pancreatic vein, carrying two or more large electrodes.
  • the system can employ one transvenous electrode and one epi-pancreatic electrode.
  • the stimulation and sensing can be done with a transplant of beta cell islets.
  • An insulin delivery tube 28 is shown for delivery of insulin into the pancreas, preferably into the portal vein.
  • Fig. 2 A there are shown two timing diagrams illustrating the burst behavior of the beta cells of the pancreas, as described above.
  • the duty cycle defined as the fraction of the burst duration compared to the overall depolarization-repolarization cycle. This represents a condition where glucose levels are low to moderate, and there is relatively little demand for insulin.
  • the lower timing diagram indicates a situation of greater insulin demand characterized by a much higher duty cycle, with corresponding greater burst activity and concurrent insulin production. In an extreme situation, the burst activity would be virtually continuous.
  • Fig. 2B there is shown a blown up depiction of the burst or depolarization portion of the beta cell cycle.
  • the onset of depolarization is rather sharp, followed by relatively high frequency spiking.
  • the spike frequency is seen to diminish, and then the electrical activity simply tails off.
  • the end of the burst period is sharp enough to be able to define with substantial accuracy an end of burst time.
  • the mean spike frequency carries information reflective of glucose level, but the duration of the burst, indicated as T B , is the primary indication insulin demand, and thus of blood glucose level.
  • T B or T B as a fraction of the low frequency depolarization-polarization cycle, may be used to determine blood glucose level.
  • FIG. 3 there is shown a block diagram of the primary components of a preferred embodiment of an implantable system in accordance with this invention. All of the components, except the heart sensor 40, may be housed in implantable device 20.
  • a stimulus generator 30 produces stimulus pulses, under control of the stimulus control block 44, for delivering electric field stimuli.
  • the terms stimulus and pulse refer to generation of an electric field at a beta cell or nerve site.
  • the pulses are delivered on lead conductors 22, 24, to the pancreas, designated by P; or to a transplant, shown as T.
  • the signals sensed at electrodes 26, 28, i.e., the beta cell electrical activity signals, are communicated to sense amplifier 32.
  • Amplifier 32 has suitable timing control and filters for isolating, as well as possible, the beta cell electrical activity from other interference signals.
  • the sense signals are processed further with correction circuit 34, such as an adaptive filter, which subtracts out a QRS template as generated by block 46 whenever a QRS is detected.
  • correction circuit 34 may also suitably correct for artifacts originating from some other source, i.e. , heart, respiration, stomach, duodemun and uterus. This is done to cancel out the interference effect of a QRS complex whenever it occurs during sensing of the beta cell burst.
  • the output of correction circuit 34 is further processed at 50, where the time duration of the burst, T B is determined.
  • Block 50 may also derive a measure of the mean spike frequency of the burst duration. This information transferred to memory associated with microprocessor 48, and also is stored at diagnostics block 52. Microprocessor 52 evaluates the stored data, and generates a control signal representative of insulin demand, or blood glucose level. Since insulin secretion, and thus insulin demand is derived from glucose driven intracellular processes, the terms insulin demand and glucose level are used interchangeably.
  • the insulin demand signal which is connected to insulin control block 55, which produces a control signal for energizing insulin pump 60, which in turn ejects insulin through delivery tube 28.
  • a heart sensor 40 is suitably positioned in the vicinity of the pancreas, as also shown schematically in Fig. 1.
  • the cardiac sensor output is connected to stimulus timing circuit 42, which times the QRS signals, and delivers a timing control signal to control block 44, the timing control signal being suitably delayed following the occurrence of a QRS.
  • the stimulus generator is controlled to produce a pulse which is displaced from the QRS, thereby enabling clear detection of the onset of the beta cell burst.
  • microprocessor 48 delivers an enable signal to control 44 and there has been a predetermined delay following a QRS, a stimulus pulse is delivered.
  • the heart sensor output is also connected to QRS template circuit 46, which generates a template signal which simulates the interfering QRS signal which would be sensed by the pancreatic electrodes 26, 28.
  • QRS template signal is inputted to correction circuit 34 coincident with sensing of a QRS complex.
  • Circuit 34 is suitably an adaptive filter.
  • the system illustrated in Fig. 3 may be subject to external control, as by a programmer 62.
  • Programmer 62 may be any suitable device, preferably a complex programmer device, although a simple hand-held magnet which is brought into close proximity to the implanted device can also be used.
  • the implanted device contains a transmitter receiver unit 61, which is in two-way communication with the programmer 62. By this means, the implanted device can download data held in diagnostic unit 52. Also, it can pick up initiation signals, to initiate insulin pumping via control 55, or initiate stimulation of the pancreas directly.
  • the functions illustrated in Fig. 3 are suitably carried out under software control.
  • Microprocessor 48 includes memory for holding an appropriate control algorithm and data. It is to be understood that blocks such as 34, 42, 44, 46, 50 and 52 may be incorporated within the microprocessor.
  • Fig. 4 there is illustrated a flow diagram of the primary steps taken in accordance with this invention, for measuring glucose level. It is to be understood that these steps are suitably carried out under software control.
  • the software program or routine is initiated at block 68. This initiation may be done automatically, i.e., every so many minutes. Alternately, it can be initiated in response to a signal from external programmer 62. Initiation may include setting of reference parameters for evaluating glucose, e.g., the correlation between T B and blood glucose.
  • the device monitors beta cell activity over a number of depolarization-repolarization cycles, to determine as best as possible the approximate onset of a next burst phase.
  • this routine it is a premise of this routine that some degree of beta cell activity can be sensed without enhancing stimulation. If the appropriate onset can be determined, then a stimulus can be timed for delivery before, but just shortly before, the start of the next expected spontaneous burst. This enables minimizing the influence of the stimulus on the burst duration, so that the subsequently measured duration reflects insulin demand as accurately as possible. After this, as indicated at 71 the system waits for a quiet period and for the sensing of a QRS. When a QRS is detected, the initiation of a stimulus is timed after a delay. The routine preferably waits until just before the next spontaneous burst, and delivers a stimulus if the delay following the last QRS is acceptable to avoid delivery coincident with a QRS.
  • a stimulus is delivered to the pancreas, and at 74 the onset of the beta cell burst is obtained, i.e., the time of the start of the burst is stored in memory.
  • the system continually senses, to measure spike frequency if available, but primarily to detect the end of the burst.
  • the system continues at 77 to monitor the heart sensor output, and determine whether a QRS is occurring. If a QRS has occurred, the interference of the QRS signal is corrected out, as indicated at block 78.
  • the routine gets the burst duration T B , as indicated at 80. Then, at 83, it is determined whether another stimulus should be delivered. If yes, the routine loops back to block 71. Although not shown, a delay may be built in between the end of one burst and delivery of a next stimulus to produce the next synchronized burst.
  • a measure of glucose level is obtained from the stored value or values of T B , in accordance with a predetermined correlation between T B and the patient's blood glucose. This correlation is suitably determined at the time of implant, and programmed into memory; it can be adjusted by re-programming.
  • the purpose of the stimulation is to improve the accuracy of the measurement. If no initial approximation of burst onset can be determined without stimulation, i.e., step 70 above, then stimulation can commence at a predetermined rate, switchably determined by prior testing and stored; the response is monitored by measuring the depolariztion. The stimulus rate is then increased until all stimuli yield capture, i.e., initiate a new burst; when this is achieved, the burst duration is measured. Alternately, vagal nerve stimulation can be applied to lower the spontaneous burst rate, enabling the electric field stimulation to take over at a predetermined lower rate.
  • Fig. 5A there is shown a simplified flow diagram of a closed loop control for an automatic implantable system in accordance with this invention.
  • the system carries out ongoing stimulation of the pancreas, and concurrent measurement of the beta cell activity, according to the illustrative routine of Fig. 4.
  • the measured data is processed and a determination is made as to whether insulin is to be delivered. For example, if the blood glucose measure derived from T B , and/or any other parameters of the sensed beta-cell signal, is greater than a stored value, then inulin is indicated. If yes, as indicated at 88, the insulin pump is controlled to deliver insulin to the patient.
  • the pancreas can be stimulated so as to increase endogenous pancreatic insulin production.
  • Fig. 5B there is shown a simplified flow diagram of the primary steps of an alternate embodiment where the implanted device responds to an external command.
  • the external command is received at 90, either from a programmer which communicates with telemetry or from a simpler device such as a hand held magnet.
  • the stimulate-measure routine of Fig. 4 is initiated and carried out, as illustrated at 91.
  • the device determines whether an insulin response is indicated.
  • insulin is provided, either by delivery from an implanted pump, or by stimulating the pancreas so as to induce greater insulin production. See Application U.S.S.N. 08/876,610 titled “System and Method For Enhancement of Glucose Production by Stimulation of Pancreatic Beta Cells. " Then, at 95, data concerning the measured glucose level and the response is stored and/or transmitted to the external programmer, for evaluation and diagnostic purposes.
  • the preferred embodiments of the invention have been illustrated in terms of stimulating the pancreas.
  • the invention is equally applicable to working the stimulation-sensing routine on transplanted pancreatic beta cells, e.g., transplanted islets of Langerhans, either allo, auto or xeno type.
  • the stimulus generator can be connected to deliver stimulus pulses to, and receive depolarization-repolarization signals from a beta cell transplant (T), exclusive of the pancreas or together with the pancreas.
  • T beta cell transplant

Abstract

There is provided an implantable system and method for monitoring pancreatic beta cell electrical activity in a patient in order to obtain a measure of a patient's insulin demand and blood glucose level. A stimulus generator is controlled to deliver stimulus pulses so as to synchronize pancreatic beta cell depolarization, thereby producing an enhanced electrical signal which is sensed and processed. In a specific embodiment, the signal is processed to determine the start and end of beta cell depolarization, from which the depolarization duration is obtained. In order to reduce cardiac interference, each stimulus pulse is timed to be offset from the QRS signal which can interfere with the pancreas sensing. Additionally, the beta cell signals are processed by a correction circuit, e.g., an adaptive filter, to remove QRS artifacts, as well as artifacts from other sources, such as respiration. The thus obtained insulin demand signal is used either to control delivery of insulin from an implanted insulin pump, or to control ongoing pancreatic stimulation of a form to enhance insulin production.

Description

SYSTEM FOR PANCREATIC STIMULATION AND GLUCOSE MEASUREMENT
FIELD OF THE INVENTION This invention relates to systems for treatment of non-insulin-dependent diabetes mellitus and, in particular, systems for stimulating the pancreas to enhance sensing of beta-cell electrical activity, from which a measure of patient blood glucose level is obtained.
BACKGROUND OF THE INVENTION It is known, from statistics published in 1995, that the number of diabetes patients in the United States is 7.8 million, or about 3.4% of the total U.S. population. This number has been steadily rising over the last 25 years. Approximately 90%, or about 7 million, are non-insulin-dependent diabetes mellitus (NIDDM) patients, in whom the sensitivity to rising glucose levels, or the responsiveness of insulin, is compromised to varying degrees. About 30%, or 2.3 million these patients, use insulin, and about 25% of these insulin users take daily measures of blood glucose levels. As a general proposition, most NIDDM patients are candidates for blood glucose level measurements and/or injections of supplemental insulin. The percentage of NIDDM patients receiving insulin treatment increases with the duration of NIDDM, from an initial rate of about 25 % to about 60% after 20 years. For this population of patients, there is a need for a flexible and reliable system and method for measuring glucose level and supplying insulin when and as needed.
The human pancreas normally provides insulin for metabolic control. Basically, the insulin acts to promote transport of glucose in body cells. The pancreas has an endocrine portion which, among other functions, continuously monitors absolute blood glucose values and responds by production of insulin as necessary. The insulin-producing cells are beta cells, which are organized with other endocrine cells in islets of Langerhans; roughly 60-80% of the cells in an islet are such beta cells. The islets of Langerhans in turn are distributed in the pancreatic tissue, with islets varying in size from only about 40 cells to about 5,000 cells.
It has been observed that neighbor beta cells within an islet are coupled by gap junctions, which allow for electrical coupling and communication between neighboring beta cells. The beta cells within the islet undergo periodic depolarization, which is manifested in oscillatory electrical spikes produced by the beta cells, often referred to as a burst which carries on for a number of seconds. The beta cell electrical activity is characterized by a low frequency alternation consisting of a depolarized phase (the burst) followed by a repolarized or hyperpolarized phase which is electrically silent. The relative time spent in the depolarized phase, during which the relatively higher frequency beta cell action potentials are triggered, has a sigmoidal relation with blood glucose concentration. The duty cycle, or depolarization portion compared to the quiet portion, is indicative of glucose level, and thus of insulin demand. Additionally, the frequency of the spikes during the active period, and likewise the naturally occurring frequency of the bursts (also referred to plateaus) carries information reflective of glucose level.
In view of the above, it is to be seen that sensing of the beta cell activity from islets of Langerhans in the pancreas may provide information for sensing insulin demand and controlling insulin delivery. Systems which seek to utilize glucose-sensitive living cells, such as beta cells, to monitor blood glucose levels, are known in the art. U.S. Patent 5,190,041 discloses capsules containing glucose- sensitive cells such as pancreatic beta cells, and electrodes for detecting electrical activity. The capsules are situated similarly to endogenous insulin-secreting glucose-sensitive cells, and signals therefrom are detected and interpreted to give a reading representative of blood glucose levels. However, in this and other similar systems, the problem is in reliably sensing the beta cell electrical activity. It is difficult to determine the onset of the burst phase, and accurate determination of the spike frequency is difficult. This sensing problem is aggravated by cardiac electrical interference, as sensing of the QRS can mask portions of the islet electrical activity, particularly the onset of the burst depolarization phase. Thus, there is a need for a system which effectively and reliably utilizes the body's own glucose- monitoring system for obtaining accurate information concerning blood glucose level and insulin demand. Additionally, it is very desirable to provide for an effective response to rising insulin demand by activating an insulin pump, or by enhancing pancreatic insulin production.
SUMMARY OF THE INVENTION It is an object of this invention to provide a system for improved sensing of pancreatic beta cell electrical activity, so as to determine insulin demand, i.e. , blood glucose level. The system includes a stimulus generator for stimulating the pancreatic beta cells with electric field stimuli so as to provide synchronized burst responses which are relatively free of signal interference and which can be accurately timed. It is a further object of this invention to provide systems for sensing insulin demand and for responding by delivering insulin from a pump, or by stimulating the pancreas to cause increased insulin production by the pancreas (as disclosed in concurrently filed application U.S.S.N.08/876, 610, incorporated herein by reference).
In view of the above objects, there is provided a system and method for improved insulin delivery for an NIDDM patient. The system is based on sensing in-vivo pancreatic beta cell electrical activity, as an indictor for insulin demand. In a first embodiment, a pancreatic stimulus generator is controlled to deliver synchronized stimulus pulses, i.e., electric field stimuli, to the patient's pancreas at a slow rate, e.g., once every 6-20 seconds. Following a generated electric field stimulus, the depolarization activity of the cells is sensed and processed to derive an indication of blood glucose level. The system monitors cardiac activity, and controls the delivery of stimulus pulses so that the onset of each beta cell burst is relatively free of interference of the heart's QRS complex. The blood level information obtained from the sensed beta cell activity can be used for automatic control of an insulin pump. In another embodiment, the electric field stimuli are delivered to transplanted pancreatic beta cells in order to enhance insulin production, as disclosed in referenced U.S.S.N.08/876, 610. In yet another embodiment, the vagal nerve is stimulated to synchronize.
The blood glucose level monitoring may be carried out substantially continuously by an implantable system, or the system may be programmed for periodic measurement and response. In another embodiment, measurements may imtiated by application of an external programmer, e.g. , a simple hand-held magnet. In yet another embodiment of the invention, blood glucose level may also be monitored by another sensor, such as by examining EKG signals or nerve signals, and the system responds to insulin demand by controlling delivery of insulin from an implantable pump or by stimulating the pancreatic beta cells to enhance insulin production directly by the pancreas, also as disclosed in referenced U.S.S.N. 08/876,610
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a diagram of a human pancreas with electrodes positioned for use in the system of this invention.
Fig. 2 A shows two timing diagrams of beta cell electrical activity of islets of Langerhans, the upper diagram having a lower burst duty cycle, while the lower diagram has a higher burst duty cycle; Fig. 2B is a timing diagram showing in greater detail the features of a depolarization burst portion of a cycle as depicted in either diagram of Fig. 2A.
Fig. 3 is a block diagram showing the primary functional components of a system in accordance with this invention.
Fig. 4 is a flow diagram illustrating the primary steps taken in stimulating pancreatic beta cells and obtaining glucose level information from the insulin- producing beta cells, in accordance with this invention.
Fig. 5 A is a simplified flow diagram showing the primary steps of an automatic implantable closed loop insulin-delivery system in accordance with this invention; Fig.5B is a simplified flow diagram illustrating the primary steps in a system in accordance with this invention, wherein the system responds to an external programming command. DESCRIPTION OF THE PREFERRED EMBODIMENTS
Referring now to Fig. 1, there is shown a diagram of a human pancreas, with an indication of some of the primary features of the pancreas. An implantable device 20 is illustrated, which suitably contains a stimulus generator and associated electronics, and an insulin pump. Of course, separate devices can be used, as a matter of design choice. A sensing lead 22 is illustrated which connects device 20 to one or more pairs of electrodes illustrated schematically at 25, 26, for use in stimulating and sensing. Although not specifically shown, a lead can be positioned into the pancreatic vein, carrying two or more large electrodes. Alternately, the system can employ one transvenous electrode and one epi-pancreatic electrode.
Further, as discussed below, the stimulation and sensing can be done with a transplant of beta cell islets. An insulin delivery tube 28 is shown for delivery of insulin into the pancreas, preferably into the portal vein.
Referring to Fig. 2 A there are shown two timing diagrams illustrating the burst behavior of the beta cells of the pancreas, as described above. In the upper diagram, the duty cycle, defined as the fraction of the burst duration compared to the overall depolarization-repolarization cycle, is rather small. This represents a condition where glucose levels are low to moderate, and there is relatively little demand for insulin. The lower timing diagram indicates a situation of greater insulin demand characterized by a much higher duty cycle, with corresponding greater burst activity and concurrent insulin production. In an extreme situation, the burst activity would be virtually continuous. Referring to Fig. 2B, there is shown a blown up depiction of the burst or depolarization portion of the beta cell cycle. It is seen that the onset of depolarization is rather sharp, followed by relatively high frequency spiking. Toward the end of the burst period, the spike frequency is seen to diminish, and then the electrical activity simply tails off. However, the end of the burst period, as shown in this representation, is sharp enough to be able to define with substantial accuracy an end of burst time. As discussed above, the mean spike frequency carries information reflective of glucose level, but the duration of the burst, indicated as TB, is the primary indication insulin demand, and thus of blood glucose level. As discussed in greater detail below, either TB, or TB as a fraction of the low frequency depolarization-polarization cycle, may be used to determine blood glucose level.
Referring now to Fig. 3, there is shown a block diagram of the primary components of a preferred embodiment of an implantable system in accordance with this invention. All of the components, except the heart sensor 40, may be housed in implantable device 20. A stimulus generator 30 produces stimulus pulses, under control of the stimulus control block 44, for delivering electric field stimuli. As used herein, the terms stimulus and pulse refer to generation of an electric field at a beta cell or nerve site. The pulses are delivered on lead conductors 22, 24, to the pancreas, designated by P; or to a transplant, shown as T. The signals sensed at electrodes 26, 28, i.e., the beta cell electrical activity signals, are communicated to sense amplifier 32. Amplifier 32 has suitable timing control and filters for isolating, as well as possible, the beta cell electrical activity from other interference signals. The sense signals are processed further with correction circuit 34, such as an adaptive filter, which subtracts out a QRS template as generated by block 46 whenever a QRS is detected. Although not shown in Fig. 3, correction circuit 34 may also suitably correct for artifacts originating from some other source, i.e. , heart, respiration, stomach, duodemun and uterus. This is done to cancel out the interference effect of a QRS complex whenever it occurs during sensing of the beta cell burst. The output of correction circuit 34 is further processed at 50, where the time duration of the burst, TB is determined. Block 50 may also derive a measure of the mean spike frequency of the burst duration. This information transferred to memory associated with microprocessor 48, and also is stored at diagnostics block 52. Microprocessor 52 evaluates the stored data, and generates a control signal representative of insulin demand, or blood glucose level. Since insulin secretion, and thus insulin demand is derived from glucose driven intracellular processes, the terms insulin demand and glucose level are used interchangeably. The insulin demand signal which is connected to insulin control block 55, which produces a control signal for energizing insulin pump 60, which in turn ejects insulin through delivery tube 28.
A heart sensor 40 is suitably positioned in the vicinity of the pancreas, as also shown schematically in Fig. 1. The cardiac sensor output is connected to stimulus timing circuit 42, which times the QRS signals, and delivers a timing control signal to control block 44, the timing control signal being suitably delayed following the occurrence of a QRS. By this means, the stimulus generator is controlled to produce a pulse which is displaced from the QRS, thereby enabling clear detection of the onset of the beta cell burst. Thus, when microprocessor 48 delivers an enable signal to control 44 and there has been a predetermined delay following a QRS, a stimulus pulse is delivered. The heart sensor output is also connected to QRS template circuit 46, which generates a template signal which simulates the interfering QRS signal which would be sensed by the pancreatic electrodes 26, 28. The QRS template signal is inputted to correction circuit 34 coincident with sensing of a QRS complex. Circuit 34 is suitably an adaptive filter.
Additionally, the system illustrated in Fig. 3 may be subject to external control, as by a programmer 62. Programmer 62 may be any suitable device, preferably a complex programmer device, although a simple hand-held magnet which is brought into close proximity to the implanted device can also be used. The implanted device contains a transmitter receiver unit 61, which is in two-way communication with the programmer 62. By this means, the implanted device can download data held in diagnostic unit 52. Also, it can pick up initiation signals, to initiate insulin pumping via control 55, or initiate stimulation of the pancreas directly. The functions illustrated in Fig. 3 are suitably carried out under software control. Microprocessor 48 includes memory for holding an appropriate control algorithm and data. It is to be understood that blocks such as 34, 42, 44, 46, 50 and 52 may be incorporated within the microprocessor.
Referring to Fig. 4, there is illustrated a flow diagram of the primary steps taken in accordance with this invention, for measuring glucose level. It is to be understood that these steps are suitably carried out under software control. The software program or routine is initiated at block 68. This initiation may be done automatically, i.e., every so many minutes. Alternately, it can be initiated in response to a signal from external programmer 62. Initiation may include setting of reference parameters for evaluating glucose, e.g., the correlation between TB and blood glucose. Following initiation, at 70 the device monitors beta cell activity over a number of depolarization-repolarization cycles, to determine as best as possible the approximate onset of a next burst phase. It is a premise of this routine that some degree of beta cell activity can be sensed without enhancing stimulation. If the appropriate onset can be determined, then a stimulus can be timed for delivery before, but just shortly before, the start of the next expected spontaneous burst. This enables minimizing the influence of the stimulus on the burst duration, so that the subsequently measured duration reflects insulin demand as accurately as possible. After this, as indicated at 71 the system waits for a quiet period and for the sensing of a QRS. When a QRS is detected, the initiation of a stimulus is timed after a delay. The routine preferably waits until just before the next spontaneous burst, and delivers a stimulus if the delay following the last QRS is acceptable to avoid delivery coincident with a QRS. At 72, a stimulus is delivered to the pancreas, and at 74 the onset of the beta cell burst is obtained, i.e., the time of the start of the burst is stored in memory. As indicated at block 75, during the burst duration, the system continually senses, to measure spike frequency if available, but primarily to detect the end of the burst. As indicated at 76, if a burst end has not been found, the system continues at 77 to monitor the heart sensor output, and determine whether a QRS is occurring. If a QRS has occurred, the interference of the QRS signal is corrected out, as indicated at block 78. Although now shown in
Fig. 4, other artifacts are also corrected with an adaptive filter. When the burst end has been determined, the routine gets the burst duration TB, as indicated at 80. Then, at 83, it is determined whether another stimulus should be delivered. If yes, the routine loops back to block 71. Although not shown, a delay may be built in between the end of one burst and delivery of a next stimulus to produce the next synchronized burst. At 83, a measure of glucose level is obtained from the stored value or values of TB, in accordance with a predetermined correlation between TB and the patient's blood glucose. This correlation is suitably determined at the time of implant, and programmed into memory; it can be adjusted by re-programming. It is to be noted that the purpose of the stimulation is to improve the accuracy of the measurement. If no initial approximation of burst onset can be determined without stimulation, i.e., step 70 above, then stimulation can commence at a predetermined rate, switchably determined by prior testing and stored; the response is monitored by measuring the depolariztion. The stimulus rate is then increased until all stimuli yield capture, i.e., initiate a new burst; when this is achieved, the burst duration is measured. Alternately, vagal nerve stimulation can be applied to lower the spontaneous burst rate, enabling the electric field stimulation to take over at a predetermined lower rate.
Referring now to Fig. 5A, there is shown a simplified flow diagram of a closed loop control for an automatic implantable system in accordance with this invention. At 85, the system carries out ongoing stimulation of the pancreas, and concurrent measurement of the beta cell activity, according to the illustrative routine of Fig. 4. At 86, the measured data is processed and a determination is made as to whether insulin is to be delivered. For example, if the blood glucose measure derived from TB, and/or any other parameters of the sensed beta-cell signal, is greater than a stored value, then inulin is indicated. If yes, as indicated at 88, the insulin pump is controlled to deliver insulin to the patient. Alternately, or in addition to delivering insulin through an implanted pump, the pancreas can be stimulated so as to increase endogenous pancreatic insulin production. At Fig. 5B, there is shown a simplified flow diagram of the primary steps of an alternate embodiment where the implanted device responds to an external command. The external command is received at 90, either from a programmer which communicates with telemetry or from a simpler device such as a hand held magnet. When a signal is received, the stimulate-measure routine of Fig. 4 is initiated and carried out, as illustrated at 91. After completion of this measurement routine, at 93 the device determines whether an insulin response is indicated. If yes, at 94, insulin is provided, either by delivery from an implanted pump, or by stimulating the pancreas so as to induce greater insulin production. See Application U.S.S.N. 08/876,610 titled "System and Method For Enhancement of Glucose Production by Stimulation of Pancreatic Beta Cells. " Then, at 95, data concerning the measured glucose level and the response is stored and/or transmitted to the external programmer, for evaluation and diagnostic purposes.
The preferred embodiments of the invention have been illustrated in terms of stimulating the pancreas. However, the invention is equally applicable to working the stimulation-sensing routine on transplanted pancreatic beta cells, e.g., transplanted islets of Langerhans, either allo, auto or xeno type. Thus, in Fig. 3 the stimulus generator can be connected to deliver stimulus pulses to, and receive depolarization-repolarization signals from a beta cell transplant (T), exclusive of the pancreas or together with the pancreas.

Claims

CLAIMS:
1. A system for sensing insulin demand of a patient, comprising: stimulating means for delivering stimulating pulses to the pancreas of said patient; sensing means for sensing the electrical responses of said pancreas to said stimulating pulses and obtaining signals representative of said responses; and processing means for processing said signals and deriving therefrom a measure of the insulin demand of said patient.
2. The system as described in claim 1, wherein said processing means comprises first means for obtaining data representative of the duration of the depolarization burst of pancreatic beta-cells following delivery of a said stimulating pulse.
3. The system as described in claim 2, comprising heart sensing means for sensing cardiac signals from said patient, and control means responsive to said cardiac signals for controlling said stimulating means to deliver each said stimulus pulse at a time substantially free of cardiac signal interference, thereby enhancing detection of said burst duration.
4. The system as described in claim 3, comprising R-wave means for determining the occurrence of cardiac QRS complexes, and wherein said control means comprises timing means for timing a next stimulating pulse at a predetermined delay following the last said QRS complex, thereby enhancing detection of the onset of said burst.
5. The system as described in claim 1, comprising initiate means for automatically controlling said stimulating means to initiate delivering of stimulus pulses on a predetermined timing schedule.
6. The system as described in claim 1, comprising external means for sending signals from an external location to enable said stimulating means to deliver stimulus pulses.
7. The system as described in claim 1, wherein said stimulating means comprises electrodes positionable with respect to said patient's pancreas so as to deliver stimulus pulses and to sense electrical activity of a plurality of islets of Langerhans within the patient's pancreas.
8. The system as described in claim 1, wherein said processing means comprises means for determining the duty cycle of the depolarization burst of pancreatic beta-cells following a delivered stimulus pulse.
9. The system as described in claim 1, wherein said processing means comprises means for determining a measure of the spike frequency of the depolarization burst of pancreatic beta-cells following a delivered stimulus pulse.
10. The system as described in claim 1, wherein said processing means comprises data storage means for storing data representative of said signals for a plurality of stimulus pulses, and means for deriving said insulin demand measure as a function of said stored data.
11. The system as described in claim 1 , in combination with insulin means for delivering insulin to said patient, and delivery control means for controlling said insulin means to deliver insulin as a function of said insulm demand measure.
12. The system as described in claim 11, wherein said system is implantable, and further comprising external means for communicating to said implantable system commands for stimulating said pancreas and obtaining said insulin demand measure.
13. The system as described in claim 1, comprising timing means for timing delivery of a said stimulating pulse to occur during a period of pancreatic beta cell re-polarization.
14. An implantable closed loop insulin delivery system for delivering insulin to a patient, comprising: stimulus means for stimulating pancreatic beta cells within a predetermined location of said patient; sensing means for sensing electrical activity of said beta cells following a said stimulating; measure means for determining from said sensed electrical activity a measure of the patient's blood glucose level; and insulin delivery means for delivering insulin to said patient in response to a determined said measure greater than a predetermined level.
15. The system as disclosed in claim 14, wherein said stimulus means comprises pulse generating means for generating stimulus pulses and lead means for delivery of a stimulus pulse to said predetermined location.
16. The system as disclosed in claim 15, wherein said lead means comprises electrodes for delivering said pulses to the patient's pancreas.
17. The system as described in claim 15, wherein said lead means comprises electrodes positioned for delivery of said pulses to a transplant of islets of Langerhans.
18. The system as described in claim 16, comprising control means for controlling delivery of a said stimulus pulse at a time when the beta-cell activity of said pancreas is in a quiet phase and at a predetermined delay after occurrence of a QRS complex in said patient's heart.
19. The system as described in claim 14, wherein said stimulus means comprises means for delivering stimulus pulses to the patient's pancreas, and control means for controlling said stimulus means to generate a stimulus pulse just before the expected start of a beta cell repolarization burst.
20. A method of obtaining a measure of blood glucose in a patient, comprising:
(a) delivering at least one stimulus pulse to a location of said patient containing pancreatic beta cells; (b) sensing the electrical response of said pancreatic beta cells to said stimulus pulse and obtaining a signal representative of said response; and
(c) processing said at least one signal and deriving therefrom a measure of patient blood glucose level.
21. The method as described in claim 20, comprising delivering said at least one stimulus pulse to the patient's pancreas, and timing the delivery of said stimulus pulse to occur while the patient's pancreatic beta cells are in a quiet phase.
22. The method as described in claim 21, comprising sensing a plurality of pancreatic beta cell depolarization-repolarization cycles, and determining a next anticipated onset of a repolarization phase, and timing said at least one stimulus pulse to be delivered just before the next expected repolarization onset.
23. A method as described in claim 22, comprising sensing QRS signals of said patient's heart and controlling said delivery of said at least one stimulus pulse to occur at a time not coincident with the QRS.
24. The method as described in claim 23, comprising sensing the depolarization burst duration of the patient's pancreas following a delivered stimulus pulse, and determining blood glucose level as a function of said determined duration.
25. The method as described in claim 20, further comprising delivering stimulus pulses to a predetermined nerve location to synchronize the electrical activity of said pancreatic beta cells.
26. A system for providing improved sensing of pancreatic beta cells, whereby to obtain information representative of patient insulin demand, comprising: stimulating means for generating and delivering stimulus pulses to a predetermined patient location; sensing means for sensing electrical activity of pancreatic beta cells within said patient, said sensing means being operatively coordinated with said stimulating means so as to sense beta cell responses following said stimulus pulses, and processing means for processing said signals and deriving therefrom a measure of the insulin demand of said patient.
27. The system as described in claim 26, wherein said stimulating means comprises nerve delivery means for delivering said stimulus pulses to a predetermined patient nerve location.
28. The system as described in claim 27, wherein said nerve delivery means comprises vagal means for delivering said stimulus pulses to the patient's vagal nerve.
29. The system as described in claim 26, wherein said stimulating means comprises pancreas delivery means for delivering said stimulus pulses to the patient's pancreas.
30. The system as described in claim 29, wherein said pancreas delivery means comprises plural electrode pairs at different pancreatic location.
PCT/US1998/006832 1997-06-16 1998-04-06 System for pancreatic stimulation and glucose measurement WO1998057700A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98913410A EP0989883A1 (en) 1997-06-16 1998-04-06 System for pancreatic stimulation and glucose measurement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/876,738 1997-06-16
US08/876,738 US6093167A (en) 1997-06-16 1997-06-16 System for pancreatic stimulation and glucose measurement

Publications (1)

Publication Number Publication Date
WO1998057700A1 true WO1998057700A1 (en) 1998-12-23

Family

ID=25368465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006832 WO1998057700A1 (en) 1997-06-16 1998-04-06 System for pancreatic stimulation and glucose measurement

Country Status (3)

Country Link
US (3) US6093167A (en)
EP (1) EP0989883A1 (en)
WO (1) WO1998057700A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014070287A1 (en) * 2012-10-30 2014-05-08 Mitosis Inc Method, system and apparatus for control of pancreatic beta cell function to improve glucose homeostasis and insulin production

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8321013B2 (en) 1996-01-08 2012-11-27 Impulse Dynamics, N.V. Electrical muscle controller and pacing with hemodynamic enhancement
US8825152B2 (en) 1996-01-08 2014-09-02 Impulse Dynamics, N.V. Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue
JP4175662B2 (en) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ.ヴイ. Electric muscle control device
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US7167748B2 (en) 1996-01-08 2007-01-23 Impulse Dynamics Nv Electrical muscle controller
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
AU3458197A (en) * 1997-07-16 1999-02-10 Impulse Dynamics N.V. Smooth muscle controller
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6884215B1 (en) * 1998-05-28 2005-04-26 Carmel Biosensors Ltd. Frequency estimation of electro-islet-graphy
US8346363B2 (en) 1999-03-05 2013-01-01 Metacure Limited Blood glucose level control
US8700161B2 (en) 1999-03-05 2014-04-15 Metacure Limited Blood glucose level control
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
WO2004112563A2 (en) * 2003-06-20 2004-12-29 Metacure N.V., Gastrointestinal methods and apparatus for use in treating disorders
US8019421B2 (en) 1999-03-05 2011-09-13 Metacure Limited Blood glucose level control
WO2003045493A2 (en) * 2001-11-29 2003-06-05 Impulse Dynamics Nv Sensing of pancreatic electrical activity
EP1289601A4 (en) 2000-05-31 2008-12-10 Metacure N V Electropancreatography
US6832114B1 (en) 2000-11-21 2004-12-14 Advanced Bionics Corporation Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes
US6950707B2 (en) 2000-11-21 2005-09-27 Advanced Bionics Corporation Systems and methods for treatment of obesity and eating disorders by electrical brain stimulation and/or drug infusion
US7440806B1 (en) 2000-11-21 2008-10-21 Boston Scientific Neuromodulation Corp. Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
US6922590B1 (en) 2000-11-21 2005-07-26 Advanced Bionics Corporation Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
US7493171B1 (en) 2000-11-21 2009-02-17 Boston Scientific Neuromodulation Corp. Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
EP2298166B1 (en) 2001-04-18 2014-01-15 Metacure Limited Apparatus for analysis of eating habits
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US7323142B2 (en) * 2001-09-07 2008-01-29 Medtronic Minimed, Inc. Sensor substrate and method of fabricating same
US6671554B2 (en) 2001-09-07 2003-12-30 Medtronic Minimed, Inc. Electronic lead for a medical implant device, method of making same, and method and apparatus for inserting same
US7025760B2 (en) * 2001-09-07 2006-04-11 Medtronic Minimed, Inc. Method and system for non-vascular sensor implantation
US6915147B2 (en) 2001-09-07 2005-07-05 Medtronic Minimed, Inc. Sensing apparatus and process
US8506550B2 (en) * 2001-09-07 2013-08-13 Medtronic Minimed, Inc. Method and system for non-vascular sensor implantation
US7192766B2 (en) * 2001-10-23 2007-03-20 Medtronic Minimed, Inc. Sensor containing molded solidified protein
US6809507B2 (en) * 2001-10-23 2004-10-26 Medtronic Minimed, Inc. Implantable sensor electrodes and electronic circuitry
US8465466B2 (en) 2001-10-23 2013-06-18 Medtronic Minimed, Inc Method and system for non-vascular sensor implantation
US7141044B2 (en) * 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
US20040137547A1 (en) * 2001-12-28 2004-07-15 Medtronic Minimed, Inc. Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property
US7247162B1 (en) 2002-01-14 2007-07-24 Edwards Lifesciences Corporation Direct access atherectomy devices
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7010355B2 (en) * 2002-03-15 2006-03-07 Medtronic, Inc. Method and apparatus for connecting various implantable medical treatment system component devices
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US7736309B2 (en) * 2002-09-27 2010-06-15 Medtronic Minimed, Inc. Implantable sensor method and system
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1578262A4 (en) 2002-12-31 2007-12-05 Therasense Inc Continuous glucose monitoring system and methods of use
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20040172084A1 (en) * 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
JP2006519663A (en) 2003-03-10 2006-08-31 インパルス ダイナミックス エヌヴイ Apparatus and method for delivering electrical signals for regulating gene expression in heart tissue
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
ES2737835T3 (en) 2003-04-23 2020-01-16 Valeritas Inc Hydraulically driven pump for long-term medication administration
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US20070060971A1 (en) * 2003-07-21 2007-03-15 Ofer Glasberg Hepatic device for treatment or glucose detection
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7986986B2 (en) 2003-08-01 2011-07-26 Dexcom, Inc. System and methods for processing analyte sensor data
US20100168543A1 (en) 2003-08-01 2010-07-01 Dexcom, Inc. System and methods for processing analyte sensor data
US8060173B2 (en) 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US7494465B2 (en) 2004-07-13 2009-02-24 Dexcom, Inc. Transcutaneous analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
WO2005051170A2 (en) 2003-11-19 2005-06-09 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8774886B2 (en) 2006-10-04 2014-07-08 Dexcom, Inc. Analyte sensor
EP2239567B1 (en) 2003-12-05 2015-09-02 DexCom, Inc. Calibration techniques for a continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP2329763B1 (en) 2003-12-09 2017-06-21 DexCom, Inc. Signal processing for continuous analyte sensor
WO2005089103A2 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
US7993906B2 (en) * 2004-05-28 2011-08-09 The Board Of Trustees Of The Leland Stanford Junior University Closed-loop electrical stimulation system for cell cultures
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
US7310544B2 (en) 2004-07-13 2007-12-18 Dexcom, Inc. Methods and systems for inserting a transcutaneous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
EP1793891B1 (en) * 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
EP1827571B1 (en) 2004-12-09 2016-09-07 Impulse Dynamics NV Protein activity modification
US8609082B2 (en) * 2005-01-25 2013-12-17 Bio Control Medical Ltd. Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US8244371B2 (en) 2005-03-18 2012-08-14 Metacure Limited Pancreas lead
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
EP1898991B1 (en) 2005-05-04 2016-06-29 Impulse Dynamics NV Protein activity modification
EP1890763A4 (en) 2005-06-02 2017-05-03 Metacure Limited Gi lead implantation
US20070016262A1 (en) 2005-07-13 2007-01-18 Betastim, Ltd. Gi and pancreatic device for treating obesity and diabetes
US20070027484A1 (en) * 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a pancreatic disorder
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US8442841B2 (en) 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US8295932B2 (en) * 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
US7519409B2 (en) * 2005-12-29 2009-04-14 Medtronic, Inc. Implantable cell/tissue-based biosensing device
EP1991110B1 (en) 2006-03-09 2018-11-07 DexCom, Inc. Systems and methods for processing analyte sensor data
CA2646324C (en) 2006-03-30 2016-06-07 Valeritas, Llc Multi-cartridge fluid delivery device
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
ES2382449T3 (en) * 2006-06-13 2012-06-08 Carefusion 303, Inc. System and method for optimizing control of PCA and PCEA systems
US20100191302A1 (en) * 2006-12-01 2010-07-29 Board Of Regents, University Of Texas System Gastrointestinal electrical stimulation for the treatment of visceral pain
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
MX2009010000A (en) 2007-03-19 2010-03-17 Insuline Medical Ltd Drug delivery device.
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
EP2152350A4 (en) 2007-06-08 2013-03-27 Dexcom Inc Integrated medicament delivery device for use with continuous analyte sensor
US7881784B2 (en) * 2007-06-14 2011-02-01 The Board Of Regents Of The University Of Texas System Hepatic electrical stimulation
EP2011495A1 (en) * 2007-07-03 2009-01-07 Sygnis Bioscience GmbH & Co. KG Use of piperine and derivatives thereof for the therapy of neurological conditions
EP2197521B1 (en) * 2007-08-31 2016-04-13 Leon Dejournett Computerized blood glucose level adjustment system
EP2227132B1 (en) 2007-10-09 2023-03-08 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
US8000918B2 (en) * 2007-10-23 2011-08-16 Edwards Lifesciences Corporation Monitoring and compensating for temperature-related error in an electrochemical sensor
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
WO2009059203A1 (en) * 2007-11-02 2009-05-07 Edwards Lifesciences Corporation Analyte monitoring system having back-up power source for use in either transport of the system or primary power loss
US20090188811A1 (en) 2007-11-28 2009-07-30 Edwards Lifesciences Corporation Preparation and maintenance of sensors
US8290559B2 (en) 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
US20090163825A1 (en) * 2007-12-19 2009-06-25 The Cooper Health System Non-Invasive Method and System of Signaling a Hyper or Hypoglycemic State
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
US8423130B2 (en) 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US8900431B2 (en) 2008-08-27 2014-12-02 Edwards Lifesciences Corporation Analyte sensor
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
MX2011004817A (en) 2008-11-07 2011-07-28 Insuline Medical Ltd Device and method for drug delivery.
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
WO2010111660A1 (en) 2009-03-27 2010-09-30 Dexcom, Inc. Methods and systems for promoting glucose management
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
EP2473098A4 (en) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
US8993331B2 (en) 2009-08-31 2015-03-31 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
WO2011092710A2 (en) 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
WO2012142502A2 (en) 2011-04-15 2012-10-18 Dexcom Inc. Advanced analyte sensor calibration and error detection
CA2839512C (en) 2011-06-17 2018-01-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
WO2013070794A2 (en) 2011-11-07 2013-05-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
EP3022668A1 (en) 2013-07-19 2016-05-25 Dexcom, Inc. Time averaged basal rate optimizer
US10569015B2 (en) 2013-12-02 2020-02-25 Bigfoot Biomedical, Inc. Infusion pump system and method
US9486623B2 (en) 2014-03-05 2016-11-08 Rainbow Medical Ltd. Electrical stimulation of a pancreas
WO2016141184A1 (en) 2015-03-03 2016-09-09 Georgia Tech Research Corporation Glucose regulation via electrical stimulation of nerves innervating the liver
US9878097B2 (en) 2015-04-29 2018-01-30 Bigfoot Biomedical, Inc. Operating an infusion pump system
CA3009409A1 (en) 2016-01-05 2017-07-13 Bigfoot Biomedical, Inc. Operating multi-modal medicine delivery systems
US10449294B1 (en) 2016-01-05 2019-10-22 Bigfoot Biomedical, Inc. Operating an infusion pump system
US10981007B2 (en) 2016-05-13 2021-04-20 Georgia Tech Research Corporation Systems, methods, and devices for neuromodulation
CA3077720A1 (en) 2017-10-24 2019-05-02 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001680A1 (en) * 1989-08-11 1991-02-21 Palti Yoram Prof System for monitoring and controlling blood glucose
US5190041A (en) 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5231988A (en) * 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
US5540734A (en) * 1994-09-28 1996-07-30 Zabara; Jacob Cranial nerve stimulation treatments using neurocybernetic prosthesis
WO1997027900A1 (en) * 1996-01-31 1997-08-07 Khvorostov Sergei Alexandrovic Electronic normalizer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003379A (en) * 1974-04-23 1977-01-18 Ellinwood Jr Everett H Apparatus and method for implanted self-powered medication dispensing
US4403984A (en) * 1979-12-28 1983-09-13 Biotek, Inc. System for demand-based adminstration of insulin
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4704029A (en) * 1985-12-26 1987-11-03 Research Corporation Blood glucose monitor
US5362307A (en) * 1989-01-24 1994-11-08 The Regents Of The University Of California Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
DE3831809A1 (en) * 1988-09-19 1990-03-22 Funke Hermann DEVICE DETERMINED AT LEAST PARTLY IN THE LIVING BODY
US5165407A (en) * 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
US5474552A (en) * 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
US5995860A (en) * 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US5919216A (en) * 1997-06-16 1999-07-06 Medtronic, Inc. System and method for enhancement of glucose production by stimulation of pancreatic beta cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001680A1 (en) * 1989-08-11 1991-02-21 Palti Yoram Prof System for monitoring and controlling blood glucose
US5190041A (en) 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5231988A (en) * 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
US5540734A (en) * 1994-09-28 1996-07-30 Zabara; Jacob Cranial nerve stimulation treatments using neurocybernetic prosthesis
WO1997027900A1 (en) * 1996-01-31 1997-08-07 Khvorostov Sergei Alexandrovic Electronic normalizer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014070287A1 (en) * 2012-10-30 2014-05-08 Mitosis Inc Method, system and apparatus for control of pancreatic beta cell function to improve glucose homeostasis and insulin production

Also Published As

Publication number Publication date
US6093167A (en) 2000-07-25
US6135978A (en) 2000-10-24
EP0989883A1 (en) 2000-04-05
US6558345B1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
US6093167A (en) System for pancreatic stimulation and glucose measurement
US6261280B1 (en) Method of obtaining a measure of blood glucose
US20020026141A1 (en) System for pancreatic stimulation and glucose measurement
US5919216A (en) System and method for enhancement of glucose production by stimulation of pancreatic beta cells
US6445952B1 (en) Apparatus and method for detecting micro-dislodgment of a pacing lead
EP2373379B1 (en) Neurostimulation with signal duration determined by a cardiac cycle
US8452398B2 (en) Method and apparatus for synchronizing neural stimulation to cardiac cycles
US6345201B1 (en) System and method for ventricular capture using far-field evoked response
US7647106B2 (en) Detection of vasovagal syncope
US20150238766A1 (en) Closed loop neural stimulation synchronized to cardiac cycles
US9498631B2 (en) Automated phrenic nerve stimulation and pacing capture threshold test
EP1116495A2 (en) System and method for automatic atrial capture detection and atrial pacing threshold determination
US20150119950A1 (en) Automated phrenic nerve stimulation and pacing capture threshold test
EP1116496A2 (en) System and method for automatic atrial capture detection and atrial pacing threshold determination
US7470233B2 (en) Method and apparatus for muscle function measurement
US20070255151A1 (en) Method and Apparatus for Adjusting Sensitivity Using Intracardiac Pressure Data
US7640058B2 (en) Biventricular heart stimulator
CN115397505A (en) Medical device and method for detecting atrioventricular block
US20130211472A1 (en) Cardiac resynchronization therapy optimization
US9555250B2 (en) Automated phrenic nerve stimulation and pacing capture threshold test
US20230053188A1 (en) Synchronizing rate responses between two cardiac pacemakers
WO2023017376A1 (en) Synchronizing rate responses between two cardiac pacemakers

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998913410

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998913410

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998913410

Country of ref document: EP